Weighing the Risks: Vivus View of Regulatory Risks in Qnexa Reprise
This article was originally published in RPM Report
Executive Summary
A good-news press release from Vivus on the resubmission and acceptance of its application to FDA for the weight-loss drug Qnexa contains an unusually long and descriptive list of the risks involved in the application. This more than boiler-plate “forward-looking” statement adds new interest to the sport of footnote-analysis.
You may also be interested in...
Setting the Stage: Qnexa and the Power of REMS
Vivus’ second trip to an advisory panel was a much happier one, with the company’s weight loss therapy garnering an overwhelming “yes” vote on approvability. The key change? A Risk Evaluation & Mitigation Strategy that will be precedent setting if approved—and that demonstrates the power of REMS even if FDA moves in a different direction with this application.
The Real Obesity Drugs Hurdle: Paying for Them
Obesity drugs are readying for round two at FDA. But if ever approved, given the airing of safety issues at advisory committee meetings, who would pay for them?
FDA Rethinking Weight Loss Standards: A Test Case for Patient-Focused Drug Development
The Center for Drug Evaluation & Research is working with George Washington University as a “neutral convener” to rethink weight loss drug development standards. That may make for an unexpected legacy from the wave of failed weight loss candidates from 2010: a whole new approach to drug development guidance from FDA.